Projects per year
Original language | English |
---|---|
Pages (from-to) | 2558-2560 |
Journal | Addiction |
Volume | 117 |
Issue number | 9 |
Early online date | 23 May 2022 |
DOIs | |
Publication status | Published - 30 Sept 2022 |
Bibliographical note
Funding Information:This study was funded by the Society for the Study of Addiction, European Monitoring Centre for Drugs and Drug Addiction. H.L.P. works under the CERCA Programme/Generalitat de Catalunya and receives funding from the Spanish Ministry of Science, Innovation and Universities, Instituto de Salud Carlos III through a ‘Juan Rodes’ contract (JR19/00025).
Funding Information:
A.G. received funding from Novartis for work outside this area (a Phase III cocaine trial). A.E. has received a speaker honorarium from GW Pharmaceuticals. A.W. is the founder of the Global Drug Survey. C.H. became a full‐time employee of GW Pharmaceuticals after the consensus meeting. D.H. has served as a paid expert witness on behalf of public health authorities in Canada in response to legal challenges from the cannabis industry. H.L. has received honoraria and travel grants from Janssen and Lundbeck. J.B. has received unrestricted research funding to study smoking cessation from companies who manufacture smoking cessation medications (Pfizer and J&J). R.V. receives consulting fees for Canopy Health Innovations and Syqe Medical Ltd, and is on the Scientific Advisory Board for MyMD Pharmaceuticals and Artiam Bio Inc. V.C. has consulted for Janssen. V.L., W.H., T.P.F., E.W., T.G., W.L., A.C.C., J.P.C., R.L.P., M.v.L., K.P., P.G., M.A.E., S.H.G., J.M. and C.M. have no competing interests to declare.
Keywords
- Assessment
- cannabis
- dose
- measurement
- standardization
- toolkit
ASJC Scopus subject areas
- Medicine (miscellaneous)
- Psychiatry and Mental health
Projects
- 1 Finished